India to pursue clinical trials of intranasal vaccines

Union Health Minister Harsh Vardhan informed that the Serum Institute of India and Bharat Biotech has been pursuing late-stage clinical trials of intranasal COVID-19 vaccines once they get regulatory approval.

“Flumist nasal spray is a vaccine that is sprayed into the nose to help protest against influenza; it is not a Covid-19 vaccine. At present in India, there is no intranasal Covid vaccine that is under clinical trials. However, Serum Institute (of India) has begun manufacturing Codagenix CDX 005, which is an intranasal live attenuated vaccine candidate for Sars-Cov-2,” he said further.

Also Read: LPG cylinder home delivery rules to change from November 1

The minister further added, “The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India.”

According to reports, the Indian Council of Medical Research (ICMR) said it will revisit its protocol for COVID-19 treatment after the WHO found some of the commonly used drugs, including remdesivir, had little or no impact on a patient’s chances of surviving.

Readers like you make Inside Northeast’s work possible

To support our brand of fearless and investigative journalism, support us HERE.

Download:                                                                  

The Inside Northeast app HERE for News, Views, and Reviews from Northeast India.

Do keep following us for news on-the-go. We deliver the Northeast.